Fasting-mimicking diet plus chemotherapy in breast cancer treatment

Código QR

Fasting-mimicking diet plus chemotherapy in breast cancer treatment

A clinical trial published in Nature Communications examined the effect of fasting-mimicking diet (FMD) during chemotherapy in breast cancer patients. The overall negative study results highlight the need for ameliorating future trial design and investigating alternative FMD-based therapeutic combin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Claudio Vernieri, Francesca Ligorio, Emma Zattarin, Licia Rivoltini, Filippo de Braud
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/9da32311aab04a9a9dc419c96b36f0f4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers
por: Maira Di Tano, et al.
Publicado: (2020)

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial
por: Stefanie de Groot, et al.
Publicado: (2020)

Risk assessment of thromboembolic events in hospitalized cancer patients
por: Federico Nichetti, et al.
Publicado: (2021)

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
por: Yuanfang Xin, et al.
Publicado: (2021)

Surgery plus chemotherapy versus chemotherapy alone in primary intestinal lymphoma: a meta-analysis
por: Yefei Shu, et al.
Publicado: (2021)

Electroacupuncture Plus Auricular Acupressure on Chemotherapy-Related Insomnia in Patients With Breast Cancer (EACRI): Study Protocol for a Randomized, Sham-Controlled Trial
por: Jialing Zhang, et al.
Publicado: (2021)

Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome
por: Yeon Hee Park, et al.
Publicado: (2020)

Neoadjuvant immune checkpoint inhibitor plus chemotherapy in rare tracheal tumors
por: Ben‐Yuan Jiang, et al.
Publicado: (2021)

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
por: Jie Zhang PhD, et al.
Publicado: (2021)

Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
por: Hong Jian, et al.
Publicado: (2017)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Jamunarani Veeraraghavan, et al.
Publicado: (2021)

Platelet-Mimicking Drug Delivery Nanoparticles for Enhanced Chemo-Photothermal Therapy of Breast Cancer
por: Pei W, et al.
Publicado: (2020)

Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
por: Taichi Matsubara, et al.
Publicado: (2021)

Analysis of Adjuvant Chemotherapy on Pathological Remission of Breast Cancer
por: Bing Jiang, et al.
Publicado: (2021)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
por: Qiao Liu, et al.
Publicado: (2021)

Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
por: Weinberg F, et al.
Publicado: (2019)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
por: Qiao Liu, et al.
Publicado: (2021)

ShenQi FuZheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis
por: Hongbo Zhang, et al.
Publicado: (2019)

Preliminary Safety and Efficacy of Proton Plus Carbon-Ion Radiotherapy With Concurrent Chemotherapy in Limited-Stage Small Cell Lung Cancer
por: Ning-Yi Ma, et al.
Publicado: (2021)

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
por: Douglas Yee, et al.
Publicado: (2021)

Characterizing intra-tumor regions on quantitative ultrasound parametric images to predict breast cancer response to chemotherapy at pre-treatment
por: Hamidreza Taleghamar, et al.
Publicado: (2021)

Klatskin-Mimicking Lesions
por: Marinko Marušić, et al.
Publicado: (2021)

A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada
por: Anifat A. Elegbede, MSc, MbChB, et al.
Publicado: (2021)

Fine‐needle aspiration cytology‐based accurate and rapid diagnosis of breast tuberculosis mimicking an abscess
por: Yethindra Vityala, et al.
Publicado: (2021)

The effects of diet- and diet plus exercise-induced weight loss on basal metabolic rate and acylated ghrelin in grade 1 obese subjects
por: Lopes AL, et al.
Publicado: (2013)

Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy
por: Ahmet Bilgehan Şahin, et al.
Publicado: (2021)

EFFICACY OF OLANZAPINE CONTAINING REGIMEN IN PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN PATIENTS OF BREAST CANCER RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY
por: Muhammad Umair, et al.
Publicado: (2019)

Postpartum Galactocele in Augmented Breast after Using Breast Pump Mimicking Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Case Report
por: Ga Young Lee, et al.
Publicado: (2021)

Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231
por: Christian Garbar, et al.
Publicado: (2017)

Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration
por: Nariman Jahani, et al.
Publicado: (2019)

The different outcomes between breast-conserving surgery plus radiotherapy and mastectomy in metaplastic breast cancer: A population-based study.
por: Lin-Yu Xia, et al.
Publicado: (2021)

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
por: Luis de la Cruz-Merino, et al.
Publicado: (2021)

Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma
por: Willard Wong, et al.
Publicado: (2021)

Mirna21 Expression in the Breast Cancer Tumor Tissue is Independent of Neoadjuvant Chemotherapy
por: Sales ACV, et al.
Publicado: (2020)

Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients
por: Chan VTC, et al.
Publicado: (2011)

Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy
por: Alberto Carmona-Bayonas, et al.
Publicado: (2021)

SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer
por: Weipeng Zhao, et al.
Publicado: (2021)

Mechanisms behind prometastatic changes induced by neoadjuvant chemotherapy in the breast cancer microenvironment
por: Perelmuter VM, et al.
Publicado: (2019)

Impact of fatigue on quality of life among breast cancer patients receiving chemotherapy
por: Fares Mohammed Saeed Muthanna, et al.
Publicado: (2021)

Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
por: Fabio Puglisi, et al.
Publicado: (2021)